Welcome to our dedicated page for Hookipa Pharma news (Ticker: HOOK), a resource for investors and traders seeking the latest updates and insights on Hookipa Pharma stock.
HOOKIPA Pharma Inc. reports asset-sale, governance, clinical and regulatory, and corporate-status developments tied to its history as a clinical-stage biopharmaceutical company developing immunotherapeutics for cancer and serious infectious diseases. Its disclosed programs included arenavirus-platform cancer vaccine assets such as HB-200 (eseba-vec) and HB-700, as well as HB-400 for hepatitis B virus and HB-500 for HIV.
Company updates have covered completed sales of oncology, HBV, and HIV program assets, collaboration-related activity, board and stockholder matters, operating and financial results, and the voluntary delisting and deregistration process for HOOKIPA common stock.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.